Muscle strength and skeletal competence: implications for early prophylaxis.
Muscle strength and skeletal competence: implications for early prophylaxis.
复制标题
肌肉力量和骨骼能力：对早期预防的影响。
DOI：
10.1007/bf02556359
复制
发表时间：
1988
影响因子：
4.2
通讯作者：
Sandler,RB
中科院分区：
文献类型：
--
作者：
Sandler,RB
骨骨骼的侵蚀折磨着全世界的人们，在它表现为骨质疏松性骨折的骨骼脆弱性之前，需要几十年的骨质流失。由于骨质疏松症的几十年的演变，具体的策略，差异化地适应所考虑的时期的问题，可以选择性地应用于控制的条件。主要在老年人中遇到的症状性骨质疏松症的治疗最好不同于旨在阻止骨质流失的围绝经期加速的治疗，并且两者都应不同于旨在支持骨骼质量的最佳成熟和随后保存的策略，作为对老年不可避免的衰退的保障。还没有出现任何药剂或药剂的组合，将补充受侵蚀的骨量，[1]第一章因此，对成年晚期和老年临床上明显的原发性骨质疏松症进行治疗干预的目的目前仅限于缓解不适和遏制骨骼进一步恶化。另一方面，在围绝经期，治疗问题围绕着骨丢失的加速率，这是由卵巢激素从生物体的调节系统中退出引起的。因此，雌激素替代成为生命周期这一阶段的治疗目标。虽然有效地抵消加速绝经后骨质流失，雌激素治疗不是没有风险的：雌激素作为内源性成分在许多组织中具有受体，其通过与外源性施用的激素相互作用可能产生不良副作用。因此，目前流行的观点是，雌激素治疗应仅限于因家族史、易患疾病和/或不良生活方式因素而增加骨折风险的女性。
The erosion of the bony skeleton, which afflicts people worldwide, requires many decades of bone loss before it manifests as the skeletal fragility of osteoporotic fractures. Because of the multi-decade evolvement of osteoporosis, specific strategies, differentially adapted to the issues of the periods under consideration, can be selectively applied to the control of the condition. The treatment of symptomatic osteoporosis, encountered primarily in the elderly, should preferably differ from the treatment designed to stem the perimenopausal acceleration of bone loss, and both should differ from strategies designed to support the optimal maturation and subsequent preservation of the skeletal mass, as a safeguard against the inevitable decrements of old age.No agent or combination of agents has yet emerged that will replete the eroded bone mass of the osteoporotic skeleton [1]. Thus, the aim of the therapeutic intervention in the clinically overt primary osteoporosis of late adulthood and old age is currently limited to the alleviation of discomfort and the containment of further skeletal deterioration. On the other hand, during the perimenopausal period the therapeutic issues revolve around the accelerated rate of bone loss, brought about by the withdrawal of ovarian hormones from the regulatory systems of the organism. Estrogen replacement became, therefore, the target of treatment for this period of the life cycle. Though effective in counteracting the accelerated postmenopausal bone loss, estrogen treatment is not risk free: estrogen as an endogenous constituent has receptors in many tissues, which by interacting with the exogenously administered hormones may generate undesirable side effects. The currently prevalent view, therefore, is that estrogen treatment should be limited to women who are at an increased risk of fractures [1] on account of family history, predisposing medical problems, and/or unfavorable lifestyle elements.